T2 Biosystems Announces Issuance of U.S. Patent for Direct Detection of Lyme Disease
May 20 2022 - 9:17AM
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection
of sepsis-causing pathogens and antibiotic resistance genes,
announced today the U.S. Patent and Trademark Office has issued
patent number 11,326,213 (the ‘213 Patent), “NMR Methods and
Systems for the Rapid Detection of Tick-Borne Pathogens”. The ‘213
Patent covers the T2Lyme™ Panel, which identifies the bacteria that
cause Lyme disease directly from a patient’s blood in 3 to 5 hours.
The T2Lyme Panel runs on the T2Dx Instrument®, the same instrument
currently used to run the FDA-cleared T2Bacteria® and T2Candida®
Panels.
Lyme disease is a debilitating disease caused by
the bacteria Borrelia burgdorferi and is transmitted to humans
through the bite of infected ticks. Typical symptoms include fever,
headache, fatigue and skin rash called erythema migrans. If left
untreated, infection can spread to joints, the heart and the
nervous system. Each year, approximately 30,000 cases of Lyme
disease are reported to the Centers for Disease Control (“CDC”) by
state health departments and the District of Columbia, however,
recent estimates suggest that approximately 476,000 people are
treated for Lyme disease each year in the United States.
Currently, there are no FDA-cleared diagnostic
tests for the sensitive detection of early Lyme disease. Laboratory
diagnosis of Lyme disease has traditionally used a two-tier process
for detecting the presence of antibodies against Borrelia
burgdorferi in a patient’s blood. Antibodies are proteins present
in the blood when the body is responding to a specific infection.
In the case of Lyme disease, antibodies can take several weeks to
develop, so patients may test negative using current FDA-cleared
diagnostics if a patient has been recently infected.
“The ’213 Patent, combined with our existing
patent portfolio of 46 U.S. patents and 16 U.S. patent
applications, as well as 73 international patents and patent
applications, demonstrates the strength of our technology to
identify a range of pathogens directly from whole blood in 3 to 5
hours, which allows clinicians to ensure patients receive the
appropriate therapy faster, and prevents the negative impact of a
delay in delivery of appropriate therapy and the overuse of
antibiotics,” stated John Sperzel, Chairman and CEO of T2
Biosystems. “This U.S. patent further demonstrates our commitment
to advance the development and commercialization of innovative
diagnostic products for critical unmet needs in healthcare.”
About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection
of sepsis-causing pathogens and antibiotic resistance genes, is
dedicated to improving patient care and reducing the cost of care
by helping clinicians effectively treat patients faster than ever
before. T2 Biosystems’ products include the T2Dx® Instrument, the
T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel,
and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2
Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active
pipeline of future products, including the T2Biothreat™ Panel, the
T2Cauris™ Panel, and T2Lyme™ Panel, as well as next-generation
products for the detection of bacterial and fungal pathogens and
associated antimicrobial resistance markers.
Investor Contact:Philip Trip Taylor, Gilmartin
Groupphilip@gilmartinIR.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Aug 2024 to Sep 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Sep 2023 to Sep 2024